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Abstract (word count: 250)  
Objective: To evaluate the effects of bloodstream infections [BSI] in patients with severe 
burn injuries. 
Methods: Retrospective (1992-2006), pairwise-matched (ratio 1:1 to 1:2), risk-adjusted 
cohort study in a 6-bed burn unit. A comparison was made between ‘exposed’ patients with 
microbiologically documented BSI (n=76) and non-exposed subjects (n=103) matched on 
burn severity (identical Belgian Outcome in Burn Injury [BOBI] score) and length of 
hospitalization (equivalent or longer than the time-to-event in the exposed patient). Main 
outcome measures were length of hospitalization and mortality. 
Results: Predominant pathogens were Staphylococcus aureus, enterococci, Pseudomonas 
aeruginosa, Escherichia coli, coagulase-negative staphylococci, and Candida spp. Median 
age was 42 years (interquartile range [IQR] 31-52y). Median total burned surface area was 
40% (IQR: 25-50%). Fifty-four percent experienced an inhalation injury. The median BOBI 
score was 4 (IQR: 2-5). The median ICU stay before onset of bacteremia was 11 days (IQR: 
5.3-19.8d). Appropriate antimicrobial therapy was initiated within the first 48h in 76.3%. The 
exposed group had a higher need for vasopressive/inotropic support (57.9% vs. 39.8%, 
p=0.017), whereas need for ventilatory assistance and renal replacement therapy were not 
significantly higher. Hospital mortality did not differ (11.8% vs. 17.5%, p=0.298). However, 
BSI was associated with an additional length of hospitalization of 25 days (61 vs. 36d; 
p<0.001), and an excess length of mechanical ventilation of 11 days (21 vs. 10d; p<0.001).  
Conclusions: In this cohort of burn patients, BSI did not adversely affect survival, but 
contributes to a substantial economic burden through excess length of ventilator dependency 
and hospital stay. 
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Introduction 
Advances in burn care substantially improved the outcome of patients with severe burn 
injuries over the past decades1. Following better acute phase survival, infectious 
complications became more prominent, with bloodstream infection (BSI) among the most 
prevalent2-5. Burn patients are at high risk for BSI because of large skin defects. The odds of 
BSI increase with burn size and depth4. Early debridement and wound closure is advocated to 
decrease infection risk, but even then colonisation of burns is difficult to avoid, potentially 
leading to systemic invasion6-8. Furthermore, burn patients are at risk for BSI because of the 
use of invasive devices, multiple surgical procedures, and prolonged hospitalization.  
Based on single center data from a 9-year period, Bang et al. reported a 23.5% mortality 
among 166 burn patients with BSI9. In an earlier study these investigators also demonstrated 
BSI to be a dominant cause of death10. In burn patients with Stenotrophomonas maltophilia 
BSI, a 31.7% mortality was found11. A study addressing burned US military casualties, 
reported BSI to be associated with a 2.6-fold risk of death12. As such, fatality rates associated 
with BSI in burn victims have been estimated between 20-30%. However, as BSI generally 
occurs in more severely burned patients it is difficult to distinguish mortality due the infection 
from mortality due to general trauma severity. Hence, matched cohort designs may be 
advocated to assess the clinical impact of BSI13. A mortality of 31% was reported in 29 burn 
patients with Acinetobacter baumanii BSI, compared to a 14% mortality in matched non-
exposed patients14. Also by a matched cohort study, Vinsonneau et al. demonstrated a 
significantly higher mortality in candidemic burn patients compared to non-exposed patients 
(30.0% vs. 7.8%)15. As far as we know no study assessed the attributable mortality of BSI in 
general (including all pathogens) in a burn population. Therefore the objective of this study 
was to evaluate morbidity and mortality of BSI in severely burned patients by means of a 
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matched cohort study that provides as adequate as possible adjustment for burn related 
mortality. 
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Methods 
Setting. This study was conducted in the burn unit of [blinded]. The unit serves a geographic 
area of ~2,608,000 inhabitants. Approximately 60–80 patients are admitted to the unit yearly. 
Our total burn population has a median TBSA of 13%, median age of 30y, approximately 
12% inhalation injury, a median length of stay of 12 days, and 7% mortality [reference 
blinded]. 
The unit has six separate isolation rooms equipped with a shower and bath. Intensivists from 
the surgical ICU and plastic surgeons are responsible, respectively, for intensive care and 
wound care. We use a mixed crystalloid-colloid scheme for fluid resuscitation. In the 1980s 
human albumin was used as colloid; since the 1990s semisynthetic colloids such as starches 
and gelatin solution have been used. We start at a hourly dose of 2 ml/kg per 1% burned 
surface area. On the first day one-half of the calculated fluid requirement is administered 
within the first 8 h following the burn, and the other one-half over the following 16 h. In the 
first 24 h after the burn one-third of the total fluid volume consists of colloids colloids and the 
other two-thirds of hypertonic saline (1 l NaCl 0.9% + 50 mEq NaHCO3). During the second 
24-h period colloids comprise two-thirds of the total fluid volume. Volume resuscitation is 
guided by urine output and hemodynamics. Early enteral nutrition has been the practice in our 
unit since 1998. Patients during the period 1985–2001 were showered on a daily basis with 
chlorexidine solution while during the last 2 years of the study period a betadine solution was 
used. Partial thickness burns were covered with silver sulfadiazine from 1985 to 1998; 
thereafter hydrocolloid dressings have been used. Full thickness burns are covered with 
cerium nitrate–silver sulfadiazine. Early excision of burn wounds has never been the practice 
in our burn unit. The use of polarized light to stimulate wound healing in partial thickness 
burns was introduced in our unit for scientific purposes in 1996. Since 1998 all partial 
thickness burns are treated with polarized light limiting the need for surgery to full thickness 
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burns and difficultly healing deep dermal burn wounds. Twice weekly microbiological 
monitoring indicates the patient’s colonization status. No antibiotic prophylaxis is used. 
Design. A retrospective, pairwise-matched (matching ratio 1:2 or 1:1 if not feasible), risk-
adjusted cohort study was performed with ‘exposed’ patients admitted to the burn unit 
between 1992-2006 whose developed microbiologically documented BSI. Non-exposed 
patients were selected from a database including all burn patients admitted to the unit. The 
study was approved by the Ethics Committee at [blinded]. 
Case finding. A prospective, case-based and laboratory-based surveillance program of BSI by 
the infection control team was used for the retrospective search for all burn patients with BSI. 
Registration of BSI started from blood cultures yielding a microorganism, with subsequent ad 
hoc determination of clinical significance, and presumed or definite inciting focus of infection 
by mutual agreement between the attending intensivist, infectiologist and microbiologist. In 
case of multiple episodes, only the first BSI episode was considered.  
Matching procedure. The purpose of matched cohort studies is to achieve reliable estimates 
of attributable mortality through accurate adjustment for confounding covariates. Hence, strict 
matching on prognostic factors is pivotal13,16-21. Therefore, exposed patients were matched 
with non-exposed patients with an identical Belgian Outcome in Burn Injury (BOBI) score22. 
This 10-point scale classification considers three major risk factors for mortality: age, total 
burned surface area (TBSA), and inhalation injury22,23. It divides age and TBSA in 
respectively 4 (0 to 3 points) and 5 (0 to 4 points) risk categories, and if present, inhalation 
injury scores three additional points. This matching procedure resulted in an equal a priori 
expected mortality and allows to assess the impact of a subsequent complication. Non-
exposed patients were selected within a 5-year timeframe before or after the admission year of 
the index BSI-patient. Non-exposed patients were required to have a ‘time-to-discharge’ at 
least equal to the ‘time-to-event’ in the corresponding exposed patient17. Selection of non-
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exposed patients was made without knowledge of outcome. If there were >2 potential non-
exposed, matching was based on the admission date nearest to that of the index exposed 
patient. 
Definitions & outcome measures. Definitions of BSI, determination of BSI sources, 
methods for antimicrobial susceptibility testing, and appropriate antimicrobial therapy are 
described elsewhere24-26. Antimicrobial resistance is defined24,27,28 as resistance to fluconazole 
for Candida species, as resistance to methicillin for staphylococci, as resistance to 
vancomycin for enterococci, as resistance to ampicillin for streptococci, as production of 
extended-spectrum Beta-lactamases for Enterobacteriaceae, and as resistance to one of the 
following agents for Gram-negative non-fermenting bacteria: ceftazidime, piperacillin, 
ciprofloxacin, imipenem or meropenem. 
Blood cultures are sampled routinely when patient’s temperature rises above 38.4° Celsius or 
bacteremia is suspected because of hemodynamic instability, chills or new organ failure. They 
are processed following the BacT/Alert® (Organon Teknika Corp., Durnham, NC) procedure. 
Susceptibility testing was in accordance with the latest guidelines recommended by the 
NCCLS or CLSI at any time during the study period. 
Clinical outcome evaluation is based on the need for organ support (need for mechanical 
ventilation, renal replacement therapy, vasopressive/inotropic support) and in-hospital 
mortality. Excess length of hospitalization and ventilator dependency were used major 
indicators of added morbidity. The excess length of hospitalization is calculated by 
subtracting the median length of hospitalization from the non-exposed group from this of the 
exposed group. As exposed patients were matched on exposure time (‘time-to-event’ in the 
exposed vs. ‘time-to-discharge’ in the non-exposed), the difference in length of stay indicates 
the added proportion of hospitalization due to the infectious complication17. 
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Statistics. Mann-Whitney U and X² test were used as appropriate. Relationships with 
mortality were assessed by logistic regression analysis. The following variables were entered 
in the regression model, and stepwise removed if p>0.1: age, gender, TBSA, inhalation injury, 
duration of hospitalisation, BSI, AKI and need for vasopressive support.  Hereby odds ratios 
and 95% confidence intervals (CI) are reported. Covariates with a plausible relationship with 
mortality or p<0.1 in univariate analysis were included in the model. As BSI was the variable 
of interest, this variable was kept in the model, irrespective of the associated p-value. All tests 
were 2-tailed. 
 9
Results 
Patients with bloodstream infection (exposed cohort). During the 15-year period 1125 
patients were admitted to the burn unit. In total, 178 episodes of BSI occurred (prevalence: 
15.8/100 admissions) in 76 patients. Fourty-three patients had multiple episodes of BSI (on 
average 3.4 episodes). Table 1 summarizes the causative pathogens involved. In 28% of the 
episodes, multiple bacteria were found. The median time between admission and onset of BSI 
was 11 days (IQR 5-20). Fifty-two episodes were primary BSI (39.4%), whereof 23 
originated from contaminated catheters (n=23, 17.5%). The burn wound was the main source 
of secondary BSI (n=35, 26.6%). In 58 patients appropriate antibiotic therapy was initiated 
within 48 hours. In-hospital mortality was 11.8% (n=9), and 9.1% (n=5) when the first 
episodes was with a single pathogen. Of the patients with a poly-microbial first episode, 19% 
died (n=4).  
 
Matched cohort. Matching was successful for all patients, but for 42 exposed patients only 
one suitable non-exposed subject was found. So, the matching procedure resulted in a 
matched cohort study with 76 exposed and 103 non-exposed subjects. Table 2 summarizes the 
characteristics of the exposed  and non-exposed groups. Compared to non-exposed subjects, 
patients with BSI had a higher need for vasopressive/inotropic support, whereas need for 
ventilatory assistance and renal replacement therapy were not significantly higher among 
exposed patients. Hospital mortality did not differ between both groups. However, BSI was 
associated with an additional length of hospitalization of 25 days (61 vs. 36d), and an excess 
length of mechanical ventilation of 11 days (21 vs. 10d). Logistic regression analysis 
confirmed that BSI did not affect survival (table 3).  
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Discussion 
In this cohort, BSI did not contribute to mortality, but caused additional morbidity, as 
evidenced by the higher need for vasopressive/inotropic agents, a prolongation of ventilator 
dependency and hospitalisation. The absence of attributable mortality in patients with BSI 
was confirmed by multivariable regression analysis.  Instead, older age, higher TBSA, renal 
replacement therapy and need for vasopressors/inotropics were identified as risk factors for 
mortality. Strangely enough inhalation injury, a factor strongly compromising prognosis in 
other studies1,29-31, was not associated with death. Probably inhalation injury contributes more 
to early deaths, while the present cohort generally includes acute phase survivors prone to 
late-onset infectious complications. 
In contrast with previous reports9,10,14,15, our study illustrates that, once adjusted for 
prognostic covariates, BSI does not necessarily impede survival in burn victims. Absence of 
excess mortality24,25,32-35, as well as dramatic attributable mortality rates have been 
demonstrated before in bacteremic critically ill patients15,19,36,37. The likelihood of survival 
depends on unchangeable characteristics such as severity of disease, causative pathogen, 
antimicrobial resistance, and patient age12,13,38-40. Essential to optimize the odds of survival is 
prompt initiation of appropriate therapy3,41-43, which was 76.3% in our study. Yet, mortality in 
patients not receiving appropriate therapy within the critical time frame of 48h was not worse 
(12.1% vs. 11.1% in patients receiving appropriate therapy). A possible reason might be that 
mostly BSI caused by (methicillin-resistant) coagulase-negative staphylococci, known as low 
virulence pathogens, were treated inappropriately. Anyhow, insufficient study-power hampers 
this particular analysis.  
As matched cohort studies are prone to selection and survival bias13,17,44, reliability of the non-
exposed group is crucial. To avoid survival bias non-exposed patients were required to have a 
time-to-discharge at least as long as the time-to-event in the exposed patient (=onset BSI). 
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Additionally, we matched subjects based on the BOBI score as this classification summarizes 
the most powerful prognostic indicators22,23. An advantage of this matching procedure is that 
the validity of the non-exposed group can be judged by comparing the observed and expected 
mortality rates. In our study, the observed mortality of the non-exposed group (17.5%) was 
situated within the 95% CI of the expected mortality (14.7-30.9) indicating a reliable non-
exposed group with an outcome in line with the expectations. Percentages TBSA differ 
statistically, but the clinical relevance of the observed difference (30% vs. 40%) is of minor 
clinical relevance as mortality associated with percentage TBSA only starts to incline 
substantially from more than 40% as indicated by Ryan et al45. Also in the BOBI score a 
TBSA ranging 21% to 40% corresponds with 1 point. Therefore exposed and non-exposed 
patients might have different percentages of TBSA while having an equal BOBI score, and 
hence have similar outcome predictions. As such, the observation that TBSA was 
significantly lower among the non-exposed is overruled by the equal BOBI scores. 
A disadvantage of this study is the single-centre design. Nevertheless, the homogenous 
standard of care used for both exposed and non-exposed patients, is an advantage of this 
single-centre approach. Another potential weakness is that exposed patients were recruited 
from a substantial time period in which favorable evolutions in survival have been observed1. 
We try to counter this problem by selecting non-exposed based on year of admission, but a 5-
year frame was necessary to match all exposed patients. This may be borderline acceptable as 
survival improved over time per 5-year period (OR 0.73, 95% CI: 0.56-0.94)1. 
In conclusion, in this cohort of burn patients BSI did not adversely affect survival. BSI was, 
however, associated with a significant excess in duration of mechanical ventilation and 
hospitalization, thereby representing a substantial economic burden. These data underscore 
the need for vigorous application of evidence-based, cost-effective preventive measures. 
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Table 1 - Microorganisms involved in 76 episodes of bloodstream infection in patients with severe burn injuries (only first episode is included) 
Microorganism n episodes (%) 
n episodes with single 
isolated pathogen (%) 
n antimicrobial resistant 
pathogens (%)a 
Gram-positive bacteria (46 isolated pathogens) 41 (53.9) 21 (45.7) 14 (30.4) 
Coagulase-neg staphylococci 12 (15.8) 8 (66.7) 9 (75.0) 
Staphylococcus aureus 14 (18.4) 10 (71.4) 4 (28.6) 
Enterococci 14 (18.4) 2 (14.3) - 
Streptococci 6 (7.9) 1 (16.7) 1 (16.7) 
Gram-negative bacteria (45 isolated pathogens) 42 (55.3) 26 (57.8) 9 (20.0) 
Enterobacter species 9 (11.8) 6 (66.7) 3 (33.3) 
Pseudomonas aeruginosa 12 (15.8) 6 (50.0) 1 (8.3) 
Sphingobacterium meningosepticum 1 (1.3) 1 (100) 1 (100) 
Klebsiella species 7 (9.2) 2 (28.6) 1 (14.3) 
Acinetobacter baumannii 3 (3.9) 3 (100) 3 (100) 
Escherichia coli 12 (15.8) 8 (66.7) - 
Serratia marcescens 1 (1.3) - - 
Candida species (10 isolated pathogens) 10 (13.2) 8 (80.0) - 
Total (101 isolated pathogens): 76 (100) 55 (54.5) 23 (22.8) 
→ Polymicrobial bloodstream infections 21 (27.6) - 3 (6.5) 
 
aAntimicrobial resistance is defined as resistance to fluconazole for Candida species, as resistance to methicillin for staphylococci, as resistance to vancomycin for 
enterococci, as resistance to ampicillin for streptococci, as production of extended-spectrum Beta-lactamases for Enterobacteriaceae, and as resistance to one of the following 
agents for Gram-negative non-fermenting bacteria: ceftazidime, piperacillin, ciprofloxacin, imipenem or meropenem. 
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Table 2 - Characteristics of patients with severe burn injuries and a bloodstream infection (BSI)(‘Exposed’) and matched non-exposed  
patients  
Characteristics Exposed group (n=76) Non-exposed group (n=103) p 
Age (years) 42 (31-52) 41 (23-68) 0.911 
Gender, % male 65.8 67.0 0.866 
Total burned surface area (TBSA), % 40.0 (25.3-50.0) 30.0 (13.0-47.0) 0.005 
Inhalation injury 41 (53.9) 54 (52.4) 0.840 
BOBI score22 4 (2-5) 4 (2-5) 0.913 
BOBI score-related expected mortality, %  20.0 (5.0-30.0) 20.0 (5.0-30.0) 0.913 
Time-to-event/Time-to-discharge, daysa 11 (5-20) 31 (14-55) <0.001 
Vasopressive/inotropic support 44 (57.9) 41 (39.8) 0.017 
Mechanical ventilation 46 (60.5) 57 (55.3) 0.488 
Renal replacement therapy  5 (6.6) 2 (1.9) 0.114 
Duration of hospitalization, days 61 (42-119) 36 (20-57) <0.001 
Duration of mechanical ventilation, days 21 (16-33) 10 (6-21) <0.001 
In-hospital mortality 9 (11.8) 18 (17.5) 0.298 
Data are reported as n (%) of patients or as median value (interquartile range). aThe time-to-discharge in the non-exposed group should be at least as long as the time-to-event 
in the exposed group. Consequently, the a-priori risk to develop  BSI is at least as high in the non-exposed group. 
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Table 3 - Logistic regression analysis to assess the relationship between in-hospital 
mortality and covariates.  
Variable Odds Ratio 
(95% confidence interval) 
p 
Age (/10y increase) 2.01 (1.37-2.95) <0.001 
Total burned surface area (/10% increase) 2.30 (1.61-3.29) <0.001 
Acute kidney injury 24.20 (1.70-344.83) 0.019 
Need for vasopressive/inotropic support 3.70 (1.06-12.95) 0.041 
Bloodstream infection 0.83 (0.22-3.16) 0.779 
Total hospital stay (/day increase) 0.96 (0.94-0.98) <0.001 
Gender and Inhalation injury were stepwise removed from the model, because these variables did not 
have a significant effect on mortality.  
